Vanguard Group’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

Vanguard Group’s Portfolio RSLS Stock Details RSLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-196	Closed	-$1K	–	4171
2018 Q3	$1K	Sell	196 -98	-33%	-$8.43K	﹤0.01%	4168
2018 Q2	$95K	Buy	294 +37	+14%	+$31.6K	﹤0.01%	4055
2018 Q1	$781K	Buy	257 +125	+95%	+$398K	﹤0.01%	3707
2017 Q4	$410K	Buy	+132	New	+$437K	﹤0.01%	3792

Other funds holding RSLS

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group's RSLS Position: Q4 2018 in Review

Vanguard Group sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q4 2018, closing a stake of 196 shares — an estimated $1K sold.

Vanguard Group first reported a position in RSLS in Q4 2017 and held it in 4 quarters. The position peaked at $781K in Q1 2018. 2 funds tracked by Wall St. Rank hold RSLS as of Q4 2018.

Vanguard Group reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Vanguard Group sold 196 ReShape Lifesciences Inc. Common Stock shares in Q4 2018, an estimated $1K.
Vanguard Group first reported a position in ReShape Lifesciences Inc. Common Stock in Q4 2017 and held it in 4 quarters.
Vanguard Group's ReShape Lifesciences Inc. Common Stock position peaked at $781K in Q1 2018.
2 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q4 2018.

Based on Vanguard Group's 13F filing for Q4 2018, filed 14 Feb 2019.